Shopping Cart
Remove All
Your shopping cart is currently empty
PROTAC ALK degrader-4
Catalog No. T215404 Copy Product Info
🥰Excellent
PROTACALK degrader-4 (Compound B8) is an ALKPROTAC degrader with a DC50 of 445.25 nM. It demonstrates significant antiproliferative activity against NCI-H2228 and NCI-H3122 cell lines. This compound causes a substantial downregulation of 390 proteins, including IGF-1R and its downstream proteins, such as ERK1/2 and STAT3. PROTACALK degrader-4 is applicable in lung adenocarcinoma research.
PROTAC ALK degrader-4
Copy Product Info🥰Excellent
Catalog No. T215404
PROTACALK degrader-4 (Compound B8) is an ALKPROTAC degrader with a DC50 of 445.25 nM. It demonstrates significant antiproliferative activity against NCI-H2228 and NCI-H3122 cell lines. This compound causes a substantial downregulation of 390 proteins, including IGF-1R and its downstream proteins, such as ERK1/2 and STAT3. PROTACALK degrader-4 is applicable in lung adenocarcinoma research.
PROTAC ALK degrader-4
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Resource Download
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | PROTACALK degrader-4 (Compound B8) is an ALKPROTAC degrader with a DC50 of 445.25 nM. It demonstrates significant antiproliferative activity against NCI-H2228 and NCI-H3122 cell lines. This compound causes a substantial downregulation of 390 proteins, including IGF-1R and its downstream proteins, such as ERK1/2 and STAT3. PROTACALK degrader-4 is applicable in lung adenocarcinoma research. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Citations
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy PROTAC ALK degrader-4 | purchase PROTAC ALK degrader-4 | PROTAC ALK degrader-4 cost | order PROTAC ALK degrader-4
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.